FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer.

J Immunother Cancer

MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ UK.

Published: June 2018

Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319091PMC
http://dx.doi.org/10.1186/s40425-017-0217-6DOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
8
immune checkpoint
8
pancreatic tumour
8
fak inhibitors
8
inhibitors combination
8
fak-inhibition opens
4
opens door
4
door checkpoint
4
immunotherapy
4
checkpoint immunotherapy
4

Similar Publications

Background: Tumor size (TS) in pancreatic ductal adenocarcinoma (PDAC) is one of the most important prognostic factors. However, discrepancies between TS on preoperative images (TSi) and pathological specimens (TSp) have been reported. This study aims to evaluate the factors associated with the differences between TSi and TSp.

View Article and Find Full Text PDF

HIFU induces reprogramming of the tumor immune microenvironment in a pancreatic cancer mouse model.

Med Mol Morphol

January 2025

Faculty of Advanced Techno-Surgery (FATS), Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.

This study evaluates the effects of different high-intensity focused ultrasound irradiation (HIFU) methods on local tumor suppression and systemic antitumor effects, including the abscopal effect, in a mouse model of pancreatic cancer. To ascertain the efficacy of the treatment, pancreatic cancer cells were injected into the thighs of mice and HIFU was applied on one side using continuous waves or trigger pulse waves. Then, tumor volume, tissue changes, and immune marker levels were analyzed.

View Article and Find Full Text PDF

The relationship between nanoliposomal irinotecan/fluorouracil/leucovorin (NFF) treatment outcomes and neutropenia in patients with pancreatic cancer has not been thoroughly examined. Thus, we conducted a retrospective analysis of data from patients with pancreatic cancer who were treated with NFF to investigate this relationship. Neutropenia was assessed according to the Common Terminology Criteria for Adverse Events across three cutoffs: A (grade 0 versus grade 1-4), B (grades 0-1 versus 2-4), and C (grades 0-2 versus 3-4).

View Article and Find Full Text PDF

To retrospectively develop and validate an interpretable deep learning model and nomogram utilizing endoscopic ultrasound (EUS) images to predict pancreatic neuroendocrine tumors (PNETs). Following confirmation via pathological examination, a retrospective analysis was performed on a cohort of 266 patients, comprising 115 individuals diagnosed with PNETs and 151 with pancreatic cancer. These patients were randomly assigned to the training or test group in a 7:3 ratio.

View Article and Find Full Text PDF

Background: Most patients undergoing pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) develop recurrence. No previous studies have investigated predictors of local-only recurrence following PD for PDAC. Our study aimed to determine timing, pattern and predictors of any-site and local-only recurrence following PD for PDAC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!